#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	9582	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2205	431.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1417	1417	C	487	C,T,A	474,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	9582	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2205	431.7	0	HET	.	.	.	C207T,G	.	207	207	C	440	440	C	547	C,T,G	429,95,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	17812	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3613	491.2	0	.	n	.	0	T695C	SNP	695	695	T	1073	1073	C	549	C	533	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	17812	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3613	491.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2349	2349	C	555	C,A	537,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	17812	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3613	491.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2423	2423	A	560	A	551	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	17812	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3613	491.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2975	2975	C	538	C	524	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	17812	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3613	491.2	0	HET	.	.	.	A1638G	.	1638	1638	A	2016	2016	A	534	A,G	281,244	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1116	folP	855	855	100.0	folP.l15.c4.ctg.1	1529	72.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1023	1025	AGC	115;117;114	A;G;C	109;112;108	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3410	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3429	99.1	1	SNP	p	S91F	1	.	.	271	273	TTC	609	611	TTC	106;107;108	T;T;C	105;106;106	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3410	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3429	99.1	1	SNP	p	G95N	0	.	.	283	285	GGC	621	623	GGC	111;112;111	G;G;C	108;109;107	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3410	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3429	99.1	1	SNP	p	D95G	1	.	.	283	285	GGC	621	623	GGC	111;112;111	G;G;C	108;109;107	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1080	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1448	74.3	1	SNP	p	G45D	0	.	.	133	135	GGC	550	552	GGC	135;133;129	G;G;C	132;132;127	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	546	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	918	58.9	0	.	n	.	0	A197.	DEL	197	197	A	509	509	A	106	A	106	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2979	111.0	1	SNP	p	D86N	0	.	.	256	258	GAC	528	530	GAC	134;137;137	G;A;C	131;128;134	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2979	111.0	1	SNP	p	R87W	0	.	.	259	261	CGT	531	533	CGT	136;135;134	C,A;G;T	133,1;131;128	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2979	111.0	1	SNP	p	S87R	1	.	.	259	261	CGT	531	533	CGT	136;135;134	C,A;G;T	133,1;131;128	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2979	111.0	1	SNP	p	R87I	0	.	.	259	261	CGT	531	533	CGT	136;135;134	C,A;G;T	133,1;131;128	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2979	111.0	1	SNP	p	S88P	0	.	.	262	264	TCC	534	536	TCC	133;134;135	T;C;C	128;131;134	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2576	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2690	95.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1513	1515	GGC	121;120;118	G;G;C,A	119;118;114,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1307	1309	GCC	141;139;139	G;C;C	136;134;137	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1310	1312	ATG	142;142;141	A;T;G	139;139;136	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1322	1324	ACC	138;139;137	A;C;C	133;134;133	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1322	1324	ACC	138;139;137	A;C;C	133;134;133	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1823	1825	ACC	134;135;136	A;C;C	128;131;130	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1877	1879	GCG	138;137;136	G;C;G	134;132;128	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1877	1879	GCG	138;137;136	G;C;G	134;132;128	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2000	2002	GGT	95;92;90	G;G;T	90;88;86	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2009	2011	AGC	81;80;81	A;G;C	78;79;80	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2438	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2529	96.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2027	2029	CCG	64;66;66	C,G;C,G;GCCC,GCCCC	60,1;61,1;58,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3848	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3251	117.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1760	1762	CCG	131;129;128	C,G;C;G	120,1;124;121	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1656	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1883	87.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	546	546	C	103	C,G	95,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1934	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1515	126.7	0	.	p	.	0	I45V	NONSYN	133	135	ATT	393	395	GTT	151;150;150	G,A;T;T	145,1;144;143	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1934	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1515	126.7	1	SNP	p	G120K	1	.	.	358	360	AAG	618	620	AAG	147;145;146	A;A;G	143;141;138	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1934	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1515	126.7	1	SNP	p	N121D	0	.	.	361	363	AAC	621	623	AAC	145;145;144	A;A,T;C	140;141,1;138	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1934	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1515	126.7	1	SNP	p	A121N	1	.	.	361	363	AAC	621	623	AAC	145;145;144	A;A,T;C	140;141,1;138	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	6900	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4851	141.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	774	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1070	71.8	1	SNP	p	V57M	1	.	.	169	171	ATG	522	524	ATG	153;153;152	A;T;G	148;147;147	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
